Vaginal Estrogen — Women's Hormones
Local estrogen therapy for genitourinary syndrome of menopause (GSM). FDA-approved with Grade A evidence. Minimal systemic absorption.
Overview
Vaginal estrogen is FDA-approved for treating genitourinary syndrome of menopause (GSM), which includes vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs. Unlike systemic HRT, vaginal estrogen acts locally with minimal systemic absorption, making it safe for most women including many breast cancer survivors per NAMS and ACOG guidelines. Multiple formulations exist: cream, ring, tablet, and insert. It is considered first-line therapy for isolated vaginal/urinary symptoms.
Indications
- Vaginal dryness and atrophy
- Dyspareunia (painful intercourse)
- Recurrent urinary tract infections
- Urinary urgency and frequency
- Vulvovaginal itching and irritation
Mechanism of Action
Estrogen applied directly to vaginal epithelium via cream, ring, tablet, or insert
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Estradiol Cream (Estrace) or Conjugated Estrogens (Premarin) | 0.5-1g cream (0.5-1mg estradiol) | Daily x 2 weeks, then 2-3x weekly | Most cost-effective. Estrace 0.01% cream preferred (bioidentical). Apply with applicator |
| Estring (low-dose) or Femring (systemic) | Estring: 7.5 mcg/day released | Insert every 90 days | Estring is LOCAL only. Femring provides SYSTEMIC levels and requires progestogen if uterus intact |
| Vagifem/Yuvafem | 10 mcg | Daily x 2 weeks, then 2x weekly | Convenient, mess-free. Low dose with minimal systemic absorption |
| Imvexxy | 4-10 mcg | Daily x 2 weeks, then 2x weekly | Newest formulation. 4mcg is ultra-low dose option. Softgel insert |
Safety & Contraindications
- Minimal systemic absorption - serum estradiol remains in postmenopausal range
- Does NOT require progestogen for endometrial protection (low-dose local therapy)
- Generally safe for breast cancer survivors per NAMS/ACOG guidelines (discuss with oncologist)
- Avoid with active vaginal infection - treat infection first
- Rare side effects: vaginal discharge, spotting, breast tenderness
- No increased risk of VTE, stroke, or endometrial cancer with low-dose vaginal estrogen